Abstract
Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.
Highlights
Anaplastic thyroid carcinoma (ATC) is a rare form of thyroid cancer and one of the most aggressive cancers in humans
In part because of ATC’s rarity and short overall survival, very little progress has been made in the treatment of this disease until recently
An understanding of the molecular aberrations in this disease has advanced the field, leading to one of the most important treatment discoveries—BRAF targeting in BRAF V600E-mutant ATC
Summary
F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. F1000Research 2018, 7(F1000 Faculty Rev):[87] Last updated: 18 SEP 2019 Any comments on the article can be found at the end of the article
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.